-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RDo9AViPc7ai2v6sNYAupCn047F2XnwXqwS2o2bmeHcPyhUE0BdUi3JNaOswWNTy
 n2Yc7NexjbKuGdYMb8A7wA==

<SEC-DOCUMENT>0001075880-07-000034.txt : 20070626
<SEC-HEADER>0001075880-07-000034.hdr.sgml : 20070626
<ACCEPTANCE-DATETIME>20070625194654
ACCESSION NUMBER:		0001075880-07-000034
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070626
FILED AS OF DATE:		20070626
DATE AS OF CHANGE:		20070625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		07939862

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20070626.htm
<DESCRIPTION>FORM6K 2007-06-26
<TEXT>
<html>

  <head>
    <title>form6k20070626.htm</title>
<!-- Licensed to: Novogen-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman;"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>______________________________________________</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Form
      6-K</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>REPORT
      OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
      THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">For
      the
      month of June</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Commission
      File Number <font style="DISPLAY: inline; FONT-FAMILY: Arial, sans-serif;">________________</font></font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;">140
      Wicks
      Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Address
      of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">___________________________________</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Form
      20-F
<font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font><strong>&#160;</strong>Form
      40-F <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(l):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
      6-K if submitted solely to provide an attached annual report to security
      holders.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule lO1(b)(7):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
      6-K
      if submitted to furnish a report or other document that the registrant foreign
      private issuer must furnish and make public under the laws of the jurisdiction
      in which the registrant is incorporated, domiciled or legally organized (the
      registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
      which the registrant&#8217;s securities are traded, as long as the report or other
      document is not a press release, is not required to be and has not been
      distributed to the registrant&#8217;s security holders, and, if discussing a material
      event, has already been the subject of a Form 6-K submission or other Commission
      filing on EDGAR.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font><strong>&#160;</strong>No
      <font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf </strong>by the undersigned,
      thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>/s/&#160;&#160;Ron
      Erratt</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Ronald
      Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Company
      Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>Date
      26 June, 2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><img src="novo06.jpg" alt="novo06"></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>ASX&#160;&amp;
      MEDIA RELEASE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>26
      JUNE, 2007</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>NOVOGEN
      REACHES SETTLEMENT WITH CHATTEM ON ISOFLAVONE PATENT INFRINGEMENT
      CASE</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Sydney
      Australia and <font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">New
      Canaan, Conn., June 26, 2007</font> - Novogen Limited (ASX: NRT - Nasdaq: NVGN),
      the world leader in isoflavone research, has settled the legal action it had
      taken against Chattem, Inc (&#8220;Chattem&#8221;) on confidential terms.&#160;&#160;The
      lawsuit alleged that certain menopause products sold by Chattem infringed
      Novogen&#8217;s US patents for health supplements containing isoflavones. (U.S. Patent
      Nos. 6,562,380 &amp; 6,987,098).</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">The
      Chief
      Executive of Novogen, Mr. Christopher Naughton, said Novogen was dedicated
      to
      the development of isoflavonoid technology, protected by intellectual property,
      in both the dietary supplement and prescription pharmaceutical
      arenas.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">&#8220;Novogen
      has also enforced its isoflavone patent portfolio against companies such as
      GNC,
      NBTY Inc., Natural Alternatives International Inc and Swanson Health Products
      in
      the USA and Swiss Herbal, Sante Naturelle, Genuine Health and WN Pharmaceuticals
      in Canada in recent years, reaching settlements in those matters as well.&#8221; Mr.
      Naughton said.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Novogen
      manages its international research and development programs that use the
      expertise and clinical research capabilities of universities and hospitals
      in
      the U.S., Australia and other key international locations.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Novogen&#8217;s
      leading dietary supplement products are Promensil, for the relief of menopausal
      symptoms, and Trinovin, for prostate health.&#160;&#160;Theses brands are
      marketed directly by Novogen in Australia, Canada and Europe, and under license
      to Natrol, Inc. in the U.S.A.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><strong>About
      Novogen</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Novogen
      Limited is an Australian biotechnology company that has patented isoflavone
      technology for the treatment and prevention of degenerative diseases and
      disorders.&#160;&#160;Over the past ten years, Novogen has conducted the largest
      and most comprehensive isoflavone clinical testing programs in the
      world.&#160;&#160;Novogen is involved in drug discovery and product development
      for disorders that are commonly associated with aging and coordinates an
      international clinical research and development program with external
      collaborators, hospitals and universities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;">Novogen&#8217;s
      investigational anti-cancer drug phenoxodiol is currently in Phase III human
      clinical trials in the U.S. and Australia.&#160;&#160;The rights to
      commercialize this drug are licensed to the Company&#8217;s majority owned subsidiary,
      Marshall Edwards, Inc., (Nasdaq: MSHL).&#160;&#160;More information can be found
      at <u>www.novogen.com</u> and <u>www.marshalledwardsinc.com</u>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman;"><em>Statements
        included in this press release that are not historical in nature are
        "forward-looking statements" within the meaning of the "safe harbor" provisions
        of the Private Securities Litigation Reform Act of 1995. You should be aware
        that our actual results could differ materially from those contained in the
        forward-looking statements, which are based on management's current expectations
        and are subject to a number of risks and uncertainties, including, but not
        limited to, our failure to successfully commercialize our product candidates;
        costs and delays in the development and/or FDA approval, or the failure to
        obtain such approval, of our product candidates; uncertainties in clinical
        trial
        results; our inability to maintain or enter into, and the risks resulting
        from
        our dependence upon, collaboration or contractual arrangements necessary
        for the
        development, manufacture, commercialization, marketing, sales and distribution
        of any products; competitive factors; our inability to protect our patents
        or
        proprietary rights and obtain necessary rights to third party patents and
        intellectual property to operate our business; our inability to operate our
        business without infringing the patents and proprietary rights of others;
        general economic conditions; the failure of any products to gain market
        acceptance; our inability to obtain any additional required financing;
        technological changes; government regulation; changes in industry practice;
        and
        one-time events. We do not intend to update any of these factors or to publicly
        announce the results of any revisions to these forward-looking
        statements.</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>ISSUED
      FOR:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOVOGEN
      LIMITED</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>LISTINGS:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ASX
      (CODE NRT), NASDAQ (CODE NVGN).</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>FOR
      FURTHER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MR
      CHRISTOPHER NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>INFORMATION</strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<strong>TEL
      011 44 (02) 9878
      0088</strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>http://www.novogen.com</u></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>ISSUED
      BY</strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
SciWords, LLC</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 144pt;"></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      Mr. David Sheon 202 518-6321</font></div>
    <div><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br><br><br></body>
</html>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novo06.jpg
<TEXT>
begin 644 novo06.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!P17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@#`P#$!`@`9````3@``````
M``!@`````0```&`````!````141'05)I>F5R(%-O9G1W87)E(%-U:71E`(#_
MVP!#``(!`0$!`0(!`0$"`@("`@0#`@("`@4$!`,$!@4&!@8%!@8&!PD(!@<)
M!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_VP!#`0("`@("`@4#`P4*!P8'"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@K_P``1"`"G`<(#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#]_****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"N)TG7(#\<-=\*JP5H?"VEW*1XYP]SJ2D_^0Q7;5\K^(OC3;^!?^"L>A_"
M_5+E$C\<_!QTTR)I<;[NQO[B9E''S,8I9&`XP(R><\7%-[')BJT*+@Y/=I'U
M);'Y-O<`9J2JUA,T^Y]@"E5VD-G/7^F/SJS4O<Z[W"BBBD`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!7X]_\`!?\`^*7BK]FW]NCX#?M&>"9BM]X?TVZGC/.V18KF,R1G'9D=
MD)Z[6/K7["=:_';_`(.DO#@C/PB\8",X@.J6*MV^80N!_P"0Z[\M498M1:NF
M?+<82E2R:56'Q1::/U'_`&7?CGX)_:2^"/A_XV_#W4%N-*\0:7!=0@'YH6*#
M=$X[.C94CU!KT+(/0U_/E_P12_X*C2_L8_$5_@K\6=5_XMWXIOX\74B?\@6\
M9BHF&#S&V[Y^"?D4]`:_?7P_KNEZ_I$6M:)?Q75K<PK);7$+;DE1AD,I'!!'
M(]0:C'86>&JOL;\.9[A\YP*DI>_%*Z-BBCI17&?1!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`449'K10`4444`%%%%`!1110`4444`%%&0>AHH`
M***,@]#0`5^87_!SIX*DU?\`9,\&^-4CR-'\;+"YV<J)[>4`Y],Q'\Q7Z>U\
M9?\`!<_X5M\0O^"9?Q"2RM3+<Z$+#6+968D@07D+3'/M#YWYUTX.3AB8R1XG
M$5%XC):\%ORM_<?SGF3R6,!7((PQSU!SD?C7Z8?\$8?^"QU_\#-7L?V6OVH/
M$C/X-N1Y/A?Q%?SD_P!CS,V5MI6.3Y#$L`3]S`'0"OS,G1@0Q;)R<^XZ`_F#
M3S=)*@5U'`(!QR*^NQ%&&)ARR/P'*<VQ.2XR-:CTW1_7AIFNV6K6D=[8S1RQ
M2*"DB2`JP(R"#T(]".#5Q6W?_KK\5?\`@B)_P5VO/`VN:9^QY^T[XHEET6[G
M\CP7XEOI<_8VV#9:2N?^69;Y4)R59U0GFOVCL)4E3S$;(95*\Y&.>]?(XO#3
MPM7E9_0&29SA\YP:K4WKU78L4445S'LA1110`4449%`!111D>M`!1110`449
M'3-%`!1110`4444`%%&1ZT4`%%&1ZT4`%%!('4T4`%%%%`!11D>M&1ZB@`HH
MR#T-%`!1110`449`ZFC(]:`"BBB@`HHR!U-%`!1110!CCQ;X:;Y5UVR)/11,
M.:N:;JFFZ@C/97<4R@`DPG<._I]#7\L3Z[J[J4;5;O!ZXN#7Z`_\$-/V_KOX
M3_$^3]F+XG:T&T3Q=>)_PCEU=S$+9:FQ*K""<X28E5`SPX`&=_'@8?/J5>NJ
M;5KGZGGWA;CLEP,\13J^TY5>R70_:=65E#J>#TI:J6U])+"K_9^&4L.<=^E6
MQTKWS\KOJ(V`<FLW5_$FB:4WDZEJD,#XR$=\''KBK\_0#-?C7_P<<ZAJ%C^T
M=X)6QNWB\WPPY8HQ'/G,,\$9/3KGI7+C,3]4H>T/>X:R&?$F<1P*ER\UW?TW
M/V#TG7M(UR#S])U&*YB5RK/"^X*<9P<=#R./>M.,`$L.X%?G1_P;C7&H7W[+
M?C*>_P!1FGQ\0IE3SY2Y5?L%EP"Q)QG<?^!5^BJ-MXQTHPM=8BBJO<Y,ZRQY
M+FM3!.7-R.UR2H97$:;V'%.,[`X*C\Z^>?VYO^"BWP6_8B^'O_"0^-;A;_7+
MQ&_L7PW:W2"XO&4X8Y_Y9HI/+GC/`R2`=ZE2%&'/-V1R87"8G'5XT</'FD]%
M8^@%O;91F255STR<9KA_'/[3W[/GP[NFL?&WQF\-:7,K;6AO=7AC=3Z$,V17
MX2?M3?\`!5W]K?\`:GU>YAN/']YX7\.3RNB:%X;O)+>,Q$`[99E(>7`X.Y@A
MSRO-<7\(OV#?VS_VA[=?$7P\^!GB?5+2?YEU6_A,$++TW1RW!C60<8RA8<<5
MXTLZC4J.%"#D?J.'\+7A*,:V;8J-)-7M=7/WPT+]NO\`9!\42+;Z'^T?X0F=
MVP@.N0J"?Q:O1]!\5^'O$%H-0T;7;.]MY,>5/9SB1'^A4D&OY\_%7_!)3_@H
M9X/TXZWJO[-VJW"1+ND_LV^M[F1![)'(9&^B@FO./AW\;/VGOV3/&[GP1XS\
M3>$-7MI@MUITC2P[BI.%FMY!AP/FX8'&3TS6+SNO3E:K2:1HO#++,?%O+\PC
M*72+:U/Z8O.\S)@8>N&%<E^T1\-;+XQ_`;Q=\+;JW2:/Q!X=O+`Q2?=8RPL@
MS^)%?!/_``3O_P""Z6@?%W5-/^$/[4MI9:#KEQB&R\3POLLKURV%1P?]0Y&,
M98@D'[N=H_1O[:MQ8F6T*RJ0<$-U!Z&O:PF,I5Z<:E+8_,L^X?S+**D\)C86
M=FK]'\S^1SQ#HE[X:U2X\-ZG$\=UI]P]M=1.FTI(F%88/3IT[<BJ-?4W_!9;
M]G^X_9]_X*"^/-,$&RR\2ZE)XBT\K'A2EY(TCJ.V%E\Q?H!TSBOEN-%<X9\?
MA7Z)AJT:E&+1_)V94)8;'U*;5K-DUHS9WB0JP!VL.H/]?ZU^X?\`P06_X*A7
M/Q^\$_\`#)OQU\1^=XP\,V"?\(WJ=VY:76+!`5VNQ^]/$`N3U=6#=0^/PV9R
M3QQ72_!SXL^.O@?\4=!^+7PVU>2PUS0-3BN["YC;'S*P)1A_$KKE&7H58@\&
MN?'8*.*@V]SU.&\\KY+CE):P>Z/ZU;<QM$/+'&.YJQTKQ#]@W]K'PO\`MA_L
MR^&?CGX7DA"ZI:E=2MUE):TNT++-$01G(<9&>JD&O;Z^-J1=.HX/H?T1AJ]/
M$X>-6GM)7#I4<L\,0WN3QZ*33I&((`&<@]Z\+_X*%?M'/^RU^RIXO^+<-TD-
MY;Z>;?1RSX)NY@8HL<'.'=6_X":RJ35.#D]D=>&H5,5B84::O*3LCUV?QOX3
MMLF?7[50OWBTX`'XUJ6TL<R^;$<AE!!QU!K^;S]@#X.>*?VG_P!L#P;\*QJ5
M^UE/J:W>LM'=,/*LX5\V0DCH#M,?^\P'>OZ-O#\)L-/AM$B(184"!CS]T<5Q
MX+&1QD.91L?2\5\-QX9Q,*'M>>4DI/R3-(G`ZU3:YLE(,THR>AP:\,_;C_X*
M&?!?]ACP0GB+XAW`OM6O&*:-X<L9P;J]8#J!_`@/!<\9(')(!_&C]K'_`(*X
M_M>_M0W]S;R>.[GPAX>D^6+0O#-]);@(3SYLX99)3Z\JI'&RHQF98?"RY'K+
ML5P_P9FW$252FE"EUE+8_=CQW^TK\`OAI<M9>//C%X<TJ>,9>WO-7A21!_M*
M6R/RKG-!_;N_8\\3W/V30OVC_"-Q(&P476H0<_BPK\"_A/\`L,_MC?M'6R:S
M\-_@1XAUBT?F/5I[<002AN=R23LBOTY*Y[9/2NM\3_\`!)'_`(*">'].:[N_
MV<;^^B@^\FG75K=2(3SS&DA)_`5P+.,8UI1=C["7AYD%"?LZV90Y_)Z']">D
M>*?#'B.QAU/1==L[RVN!F"XM;A7CD&,Y5E.#P.U7[9PY8AP1Q@"OYF/!'QF_
M:?\`V0OB`1X5\9^*O!NMVI'VO3[F66`L.0!-;O\`+(/<@CWS7Z<?\$Y_^"[6
MB_$K5+3X0?M96EEHFM7+Q0Z?XGB<QVEW(3M`F5LB%B=H#`["6QA>,].%SBA7
MER5%RR\SR,]\-\TRG#_6<+.->EU<=S]-:*K6.I1W\"W,&UT<91D?(;Z&K->P
M?G*=PH/2FRR&-=P7/':O(_VK?VT_@M^QU\/I_'WQDUU+1`=MC81.&N+V0CA(
MDZL>Y/11R3BIG.-.#G)V2-L/1K8JNJ-&+E)[)'J)O[2*,RRW2A=P'([GM7/>
M,_C5\)/A^BOXZ^)&B:0-F\#4M1CA.WUPY%?B)^UI_P`%LOVJ_P!H?49M$^%N
MMMX!\/898;?1ILWLBJ?O2W"\J2.=J;0,9SC->">"/V:_VO?VEKEM7\&?##QS
MXQ:X</)JK6MS<PR,Q)W//)\N3@\E@#CJ<5X<\ZO*V'AS(_3<O\,JSP_M<UQ4
M*'EU/Z"!^V_^R(SB)?VCO!Q+=`-<@Y_\>KJ_#?QX^"OC"X2S\*_%3PYJ4TA(
M2*QU>&5C@9/"L3T!K\"5_P""2G_!1<+]I'[+NJ$@<$ZGIY8?@9\UQ'C;]D']
MLCX+1MJ'C/X&^-M$MHL-)?V^DW7D]0`3+""@YP`<]3VZTEG&)7QTF=R\-\AK
MZ8?,X.79L_I174+25]B,C8&>/>K","N0N`.U?@+_`,$__P!O[]N?P3\;O"WP
MB^'_`(\OO$]KK>MV^F_\(]XDGENHXU:55;:[,9(BBLS,0Q`"\C@5^^6DO<2:
M7"]V`)3'^\"]-W?&:]3"8N&*H\]K-;GP/$W#&)X:Q4:56HIJ6JL^A:+*$!)^
ME9USXBT"TN7MKO5[:.0`$QRR@'!Z'!_G5R0%T4`]".W7FOQ)_P"#@/5=4L?V
MS-,M(-1G6-?"%NP6.8J-WFR@G'3)P/RIXO%+"4'5>I'#&0?ZQYI'!<_)=7N?
MM./%?AGOKEE_W_6D_P"$K\,_]!NR_P"_ZU_-G\+/V:?VL_C=X=;QA\(O@]XQ
M\1:5'</`^H:5932Q>:H4L@9006&\<5T__#`?_!0+_HV?XA?^"BX_^)KRXYS5
MDM*3/NZOAIE="JZ<\S@FM&K_`/!/Z)O^$J\-$9_MNRP.O[]:=!XK\.7;^3!K
M$#L.BI(">W8?6OYUF_8#_P""@GWA^S-\1"!UQI%QC_T&O>O^"97['G[9/P\_
M;6\&^-/B-\"/&.EZ'933&^U#5M)F6"%3#(`&8C'WMO7-:4<TQ%2I:5)I'FYE
MP+EF7X">(IYA";CT35_S/W$R#5>_U*PTU!-?7*1+@D,YP..M3K]T9]*^0/\`
M@N4UU!_P3Y\4WMI)L>*YL_G`Y`-Q&"`1R,C(KUJLU3I.?8^"P&$>.QE/#IV<
MFE]Y]4?\)AX8G?9'KEH2#C!F`_K5U+N$LH2,$,,A@*_EB_M[65/_`"&+PD<9
M%R1_*OVH_P""(W[?,O[1?PE'P2^)&L+/XO\`"=N%6:>8M)?V(&V.;)Y9@0RM
MUZHW\6!Y66YQ3QU5P:MV\S[SBOPWQ_#F7K%PJ\ZZKL??T9&XCOBG5#;.9)'.
MWY>-K`]:FKV3\XM8K7#0Q@%SP.Y%9C>-?"B7<EJWB"V$L;E)(_,&4(SD$=NA
M_*M&]ADE@<1S;&*D*VW.#ZU_-[_P4`US6X?VV/BO!)K5Z\<?CS50(S>.$"":
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MF+]L;]GR'3/%.LC_`(37PK$EGXAB9UW7*\B*[7CE77&>.'1ATKZ]R!P37\U/
M[&'[4?CW]AS]I&P^*.GVER#9SO9>)]%W8-Q;9(FB*G!5E*@C/0Q\]17]%_PQ
M^)W@OXO^!M*^(G@+5XK_`$K5K1+BSN8B</&PR#SR/0@\@@@\BOHLGQGMZ/LJ
MC]];GXGQ[PS#(LS=?#?[O5O*#[=U^)TD^"`:_&;_`(.0`#^TCX&SV\*N?_([
M5^RSLI..^17XT_\`!R!_R<EX'_[%1O\`TH:GG;_X3I'1X6K_`(S*C_AE^1]!
M_P#!M[Q^RGXR/_519O\`T@LZ_10D;]N>HK\Z?^#;X_\`&*WC+_LH<W_I#9U^
MBY568ENP%:91_N<3Q..K?ZUXJ_\`,_R/,OVJ?VC?"?[*/P5USXT^-ILVFDVQ
M:*V#A6N9CQ'"F?XG;`%?SK?'[XY_$K]JKXM:A\6/B+>2ZAK.K7(BM+=%+_9T
MW8CMXE/.Q"<`#DD^M?HC_P`''GQ[N+K7?!7[-NE7[+;P!M:U:->DCMNA@!^G
M[T_C7A__``0V_95L_P!H']J0?$;Q3IHNM#\!P+>2PS1Y6:^<LL(;_=(:;']\
M`]J\;-:\L=C5A(GZ3P'@L#PUPM5SW$1_>-/EOWZ?>?5__!+C_@C3X+\`>%M-
M^/'[4OABVU;Q1>QQW6E>'KZ/?;Z4A&Y#*A!$LX!SD\+G`&<U^C5AHNEZ3IZ6
M.G6,<$,8Q'%$H"J.P`'0"K5G%Y>?H/ZU/7TF&PU/"TE"*V/R'-\YS#/,7*OB
MJC=^E]$5?L=M(C12*'5AAE89!KP[]M']@;]G_P#;)\"OX?\`B+X+M4U6&-O[
M'\0V<"I>6,N`%9)!@D#C*'*D#ITKWNHKDD8(]#6E2C2K0<9JZ9P83$5\!5C4
MH2LT[H_FD_:Z_93^(G['OQGU'X4?$"RWO$OF:5J,$96+4;7(VS*3W7."ISM8
M$=1FOT\_X(8_\%"M4^-OA"?]F'XOZY)>>(_#UK]HT/4+B7,E_8C"&-L\M)&<
M$GNLBYY!SZ-_P6\_90L?V@/V4;[Q[I&CH_B'P0&U*QN`GS/;`#SX21R5*@-]
M8Q7X[_L=?'#4?V=OVF_!?QAT^[=/[(UJ$705MHEM7)BEC8#@YC=QGWKY50>4
M9@HI^Y(_?/;4?$#@R<JZ3Q%'JM]%I]Y^C/\`P<N_LIMXZ^"GA?\`:=\*Z-YN
MH>#;J33];:,'+V-R4\MFYY,<JA5]YSGH*_$ZXMM@RIQ[BOZO?B?\/_!O[1/P
M>U;X;^*[-;S1?%.C2VMW$QX:*6,C<O<,-P*GL0I[5_,1^UG^S;XT_9+_`&@_
M$O[/OCM#]JT"^*V]TR[5O+9@'AG7/9XV4^QW`X*D#]1RG$J4?9G\.>(635<-
MC5C8K=^]IM;3]#S.GQJQ0NAP58$$=B#D?RIE/B(`;-?0-I:GYC=K8_2O_@W)
M_;%G^$_QVU#]E?QEJ[#1?',+7.A!Y.+?4X@H*Y;H)8L@8_B11C+5^ZV1ZBOY
M'_A/\2?$7P;^)>@_%7PG<B'5/#NJ6]]9,6/^LBE$@''\)`9&'<-7]5'P1^)>
MA_&KX6^'?BSX78-IWB+1X-0L3NY\N6)9`#[@LP_"OE<WH*-7VBZG[7P!FCKX
M&6'F[RCJO\CLYY-K`>H.*_)7_@XT_:,GO-<\*?LPZ/J),,.-;UBWC8?,Q62.
M%6[\`R-CU(/4`C]6?$6HV6BZ0^JZF^R&VB>220C[@522WM@`U_-_^V/\8M7_
M`&N/VO?%?Q%TN.:ZEUSQ"+31+>-<EK='6"VC0>K(J'\SV-?%9[B)0PGLX;R/
MZ-\+\I6/SUXNJOW=&/,[[7/T`_X-SOV:([;P[XJ_:GUK3MHN[HZ)X?:099HD
MVR7#@^F]E3ZQFOT*_:C^/_@W]F'X'^(?C9XWO#%9:)I\DZQJ?GGDP=D2`]79
ML*!ZD5E?L<_`2V_9B_9T\*?!BQ@7&DZ:D=[)&`!+<L`TLGXN6-?G[_P<<_M`
MWT$/@?\`9KT*Y:..83ZUK<8;J1B.U!_V0WG,1URJUHY/+,J4E\21P\D^->.)
M4U\,I_=%:_H?G9^TM^T/\1_VJ/B_JOQ:^)NIF[O=2FVP6@;=#:0#`2"-<8"J
M!CIR2Q.2Q)_3O_@EK_P1I\)>!]+T[XZ_M8^%8=4\0W'[_2O#%ZI>WTU"ORM-
M&1B2;D\-E4(!QN'R_*?_``1"_92TW]H7]K3_`(3;Q1IJ3:#X%MUU*9)4W":]
M:0"V7GC@JSG'=/<5^\R(%4+C@5PY1@8XC_:JVLGL?9^)'$U3+9+(\LER4XI<
MS6FI0T[1=)TFT2RT_3X;:%%`CAAC"JH`P``.@]JG^S6I<.5!(Z$CI5FBOI.5
M7/Q'WGJW=G@W[8G["G[/?[87@.X\.?$WP5`=0\EAI>OVZ[;NS<\@H_IVVG*X
M)XK\&OVQ?V1_B-^QK\8KKX6^/87DA7<^AZLL;)'J%J#A9ESRK<_,O5#QG(S7
M]+K`E?EZ]J^-/^"V/[)%E^T?^R5J/C#3],637?`5M<ZSIT@`WO"J`W,0]=T2
M%@.[Q)UQ7E9IE]'$4_:)6DNQ^@\"<7X[(\>L-4GS4*CLT];7/'?^"%7_``4*
MUSXN^')OV4OBSX@:ZUOP[8^=X;O+E_WEY8J?FBSU=XLK[[&7.2*_2ZOYBOV5
MOC;J?[.?[0/A7XT:5=R1_P!C:Q#<7JQC)D@9]L\8_P!Z-B![*1W%?TS:=JUK
MJ=C#>VTRR+/$'C93D,",Y%3D^,GB*3IR=W$OQ(R&EDV;^VH1M2JJZ]>OYG*?
MM%?&7PQ^S_\`"C6/B]XTU-;72]"T^6ZNF+`%]@R$7/5F.%`[E@*_G9_:_P#V
ML_B9^V=\9[WXL?$"_F,<K^5HFEJ2(K*U!'EHBCN>&+'))8\XK]$_^#C?]HRZ
MTWPGX+_9OT"[=1J\\VK:['&Y4F&(I'`GIAI&E8CK^Y'J,_-/_!#+]DBS_:%_
M:G_X6%XLTM)=#\`01Z@T<JEQ/J#2+Y"\\;5VM(>^8X_>N',\15Q6+6%CMU/K
M.",!A.'.&ZG$.)2<]>2_X?>SZC_X)??\$8/!_A71M-^-O[7OA*'5M=N5$^F>
M%-07?!IH*Y5ID/#S<G@_*N!P6!V_I9HOAK0?#UBFF:'I,%G;QJ!'!;1A%08Z
M`#@#V%:84*,`=*6O>PV$HX6GRTT?DV<YWF6>XR6(Q<VV^G1%86D(X$>WUP<5
M#<Z+I=]9FUO+*.2,C:5<=JOT5NDK:GDJ\97B[,\BM?V+/V8=-^-MC^T+I/P?
MTFR\7V$$T,&KV<9B=Q(NTEU0A78#(#,"1N;!&37J<6(8C'M(VKG![5:P/2BB
M,(QO9;FE>M6Q$E*I)MI65W<KD_)GW7^8K\0?^#@\Y_;4TW_L3[;_`-&RU^WK
M_P"L;ZK_`#K\0?\`@X.Y_;4TT?\`4G6W_HV:O(SM7P27H?H7A9*,.+8.7\K/
ML;_@WE@CD_8?U$L@&/'M\=WOY%M_@*^^?*@_NC\J^!_^#>9T3]AK427`_P"*
M]OB1G_IWMZ^^MT`&1M_*N_`7EA(W['RO%C3XFQ7+I[[_`#&BWB8@@X`ZC'6F
M-:V[,=L*G=][MG_.*E6XB0X+*`>].9]V'09!Z&NKJ?/KW%?N2#I7R%_P7+D"
M_P#!.KQA'GEKBR_]*8Z^O:^/_P#@N?\`\H[/%W_7Q9?^E,=<^+_W:?H>]PY%
M3S[#1?\`/'\S\:OV&_V=+?\`:H_:#@^!]Q-Y<NL:+JAL9W)"PW,5C-+"_P`I
M!.)%3(.1ANE9_P`&OBC\7/V)OVD[3QCIMI/I/B#PIJK0:GI]PV`Z_=FMI`.-
MK(2.F1P1@@$>T_\`!#[!_P""DG@T#_GQU/\`](I:^E?^"]G[!,TT0_;-^'NB
M;!"D5MXTM[8`;UW;(KX@=QOV.?[NTX`0FOD<-AJE3`QK4='%L_H',\_I4>+9
MY1CG>A6BK7Z/5'Z1?LN_'_P9^TQ\'='^,?@6_$NGZQ813+&S#S+=R/GAD'\+
MHV58=B*]%!!&0:_#;_@B-^WJ/V>_B_\`\,\^/]4">$O&MU''8FY;"Z?J!)"@
M?W5DW%6ST(7.,&OVZL9;<VH:$;E;)#8ZGO7U.`Q4<70YENC\)XLR&IP[FLJ#
M^!N\7W3+$_$1^AK^:_\`X*$\?MO_`!='_4^:O_Z.>OZ4)_\`4GZ5_-A_P4)_
MY/@^+G_8^ZO_`.CGKS,^_AP]5^9]MX0ZYMB%_P!.S]-OV9/^3;?A[_V(^D_^
MD<5%2?LQ?\FU_#S_`+$;2?\`TCBHKK6QY567[V7JS\>O!0_XK/2!_P!12W_]
M&+7]07A>W^T^#;!&;@V,088Z@H,C\J_E^\#_`/(ZZ/\`]A6W_P#1JU_4+X*.
M?"M@A_Y\XL?]\"O.X<;E2FV?2^,S_?X677E9^.__``7:_8*7X1_$`?M5?#C3
M2-"\2W*KXF@MHPJ65^1M\\@=$E4-N_V\G^+C6_X(/_\`!0!_`WB\?L@?$[55
M_L[5YWG\)W%U/_J+DJ2]JA(QL;864<89B.=W'ZJ_&WX*>`OCU\.]6^%GQ&TI
M;W3=7LGMKB%C_"V""/<$`@]OQ-?SM?M2?L\_$O\`8<_:1U#X<ZS<7$&H:#?)
M>:'K$49C%S#NW074?<#Y<''\:N.F*>84IY=CEBX+W>I'">-P_&/#TLBQ;_?1
M5X-]?^&T/Z4+>=;D>8%&.""#U'-?C?\`\'('_)R7@8YZ^%'_`/2AJ^^?^"6/
M[;6G?MH?L\P:WJM_"/%.@+%8^*;-6`9)PI"2[>H215WCW+>E?`O_``<A'/[2
M'@7:?^97;_T>U=>;5*=?*G.&J9XWAU@L3EW'D<-65I04T_N/H/\`X-OE_P",
M5?&9_P"JB3#_`,D;.OT5D&3G/45^=?\`P;?_`/)JOC/_`+*+-_Z06=?HJW/Z
M?SK;*E_L,3YGCG7BG%_XOT/P/_X+J>)+K6_^"BOBO3)KG>NDZ;I5G&@;.P&R
M6<`^G,\A_$5]M_\`!N5X,M-._9/\4^+XPBW6J>/+B">0)R\,-K;&,$YZ@RR'
M_@5?%_\`P7C\*W/A_P#X*&ZWK.`!K>A:==H0@Y"VYMN?7F(5]@?\&W/Q#L]5
M_9\\:_#1[M/M6D>,#?>6#UAN;:)5/YP/^=>5A(0_MR4GN?I/$,:L_"O#>S>B
M<;GZ2VRE4&6[8Z5+3(?Z"GU]2?AK=V%,FC\SOC@T^HYG*E0.]%KBD[*YC^,?
M"FF>*_#&H^'=802VE]8RV]S$PR'C=&1@?JK$?C7\N.JZ<NF:K/IK2^8L%R\3
M-C&X*Y4GVX%?U"?$_P`;:9\//`>M^-M;G"6>D:9/>7+9'"11%R/TK^7>ZFN]
M7U9[J67#W,I;9@<LS$G]2:^8XE2_=/JG_D?MG@^I^SQDG\-E]_O']*_[%>MW
M?C']DKX;>+=3E$EQJO@'2+J=RO)D>RB=B?7):ODC_@NO_P`$UY_VL?A3%\=?
MA+HAN/'WA"V;%K;Q_/JMB`6>`=S(IPR=>K#C.:^QOV2_"DO@7]FCP!X)G4*V
MC^#-,LBH[>5:QQ_^RUW\EK#.I2;O^E?586K.DHS3ULC\-XAP%#-'B*$]G)_F
M?R%FQDC9XIB5DC8K)&1RC`X(/I4()0D$5^KO_!;G_@C[=^&+_4/VROV8?#$S
M:9(GF>-O#.GP;FM\')O85'.W!'F)CY=I88`(K\IK@JP5U7&[)QR>.,<D?_JK
M[3"XE8J-T?S=G.38K)L6Z51:=!/.!P#&/SK^@?\`X-WOC?+\5?\`@GS8^$[^
M^\^_\#>([S1959OF6#"7$!QV&R?8/^N9^@_GT'45^K/_``;`_%N;2OBI\3O@
MQ/>A%U32+35;:`GEG@D>-L#UVS+D]^/05R9O24L-=;H]W@+%?5<\2Z23/OG_
M`(+*_M%K^S[^Q)XC73K_`,C5_%D1T#2V1L.IN5*2LN.XBWX/8D5^7/\`P1,_
M9X'QS_;4TC6-8T83:+X&M3K=Y(02AF4K';H?]K>V[_=1J])_X."_VBY?B%^T
M7HGP)TS5!)9>"[*2:]1)1M-Y<E2RMC^Y"JX/4;LC!YKZU_X(*?LZ?\*G_9*_
MX6QK>G^3JGCR[-T"W#)9PLT4(/\`OX>0?[+BOS*<5CLTBEM`_M^A_P`8KX<R
MJ;5<4[>?+V^X^\)8R5(#``K\HQT-?@W_`,%U==N=8_;_`-7MKB=F%CH5C!&A
M/"C:S\?BQK]YI&`5]WW0.N.E?A/_`,%Z_"]WH?[>=WK,BC[/J_ARRN+9MN,A
M0T;?7E?UK?/_`/<3QO"F4%Q4HRW<;'UW_P`&YO@2RL_V;?%OCI#B?4_%I@D)
M&?DAACVC_P`B/7Z2D'&`<5^8_P#P;C?$JUO/@KXW^%TETAN-.\11WL4.>?+G
MA"Y_.%C^%?IQD=,UU94_]@@?/<;PJ4^*\5">ZD%%%%>@?*A6%\1]*M=<\':E
MH]ZH:*ZL)H9`1D%60J>._!-;M<S\7O%&F^"_AYK/BO5[A(K73=(NKNX>1L!8
MXXB[$^P`J*G\-FM!2=>'+O=?F?S!^--&M/#GC+5_#UB28;'5;FWC+=2$E90?
MTK^D']BC7KOQ?^R9\.O$=Y<%WN?!VG.[GJQ^S1J23[E2WX^U?S>>+=9C\1^*
M]3\0HH47^H37(4'IYCL_'YU_2=^R9X3N_`/[,?@'P;?0>5/IWA'3X)XQGB18
M%##\Z^:R&*6+J-'[9XM17]CX!3^)I?\`I*O^A^.O_!>[7KW4OV^+O1IY-T.F
M>&;&*W![!O,<_JU?87_!N7X5T^Q_9@\6>++?B[U+Q<8)FV_P0PQ[1_Y$:OD_
M_@X%\'W6B_MQP>+&C80:]X1LIH21P?++QM^H'YU])_\`!M[\3;/4OA/XZ^$L
MMTGVC2]:BU&*(?>V31A2?SB`J,-_R/))FF>P=7PIP]6EM[M_Z]3].Z***^K/
MPH*8TI`!"]:?6;XCOY=-T&YOH)-KPPED8C(!QZ>E*^HXQ<I**W;L:._CGTIO
MFC&<5^&]Y_P7D_;[MO&KZ5_:?A3RDU1K<J/#9;:GFE.<2Y!Q@Y/KTK]L?!&M
M3^(O!^FZU>,#-=6,<LQ48&\J"<#L,YKFPN+IXIRY>A[N=\.9IP_&G+&0LJBN
MC1?[S'W7^=?B%_P<'C'[:FFG_J3K;_T;+7[>OU?ZK_.OQ"_X.$/^3U-,_P"Q
M.MO_`$;+7GYW=X'3^MCZ7PO:7%M/TZ'`?L3?\%:OB]^P]\)9OA)X#^&OA[5K
M2;69M1:ZU2:X$@>1(T*XC<#`$?Z^W/L7_$1O^TW_`-$4\&_]_P"\_P#CM=A_
MP1R_X)U?LC_M7?LM7GQ$^-_PT.K:S#XLNK-;H:K=0_N4B@95VQ2*O!=CG&>>
MM?7'_#D7_@G-_P!$+;_P?W__`,>KEP^'S=T(^SJ)+S1]=GN=>']#.*\,5@Y2
MJ*3N[O\`S/A4_P#!QI^TRQWM\$O!IV*2/W]YP?\`O[7ZG_L;_&[7/VAOV9?!
MWQL\2:7;65[XBT6*]NK2T9C'"SY.%+$DCZUXQ+_P1&_X)S@9'P/9?7_B?W_(
M]/\`75](_"KX7>#O@KX"TKX6_#S118:!H=DMMIUGYSR>5$O1=SDLV/4DFO4P
M5',(/_:)J2\C\^XHS3A;&481RO#NF[Z[_JV=9UKX^_X+G_\`*.SQ</\`IXLO
M_2F.OL$8QQ7Q]_P7/_Y1V^+O^OBR_P#2F.NG%?[M/T9Y?#/_`"4&%_QQ_,_,
M/_@A\<?\%)O!I_Z<=3_](I:_=SXA>$/#WCKPAJ7@_P`3Z5%>6&IV3VMW;2Q[
MEE1QM*D'C!!Q7X1_\$/S_P`;)?!O'_+CJ?\`Z12U^^KQQ[?GR?>O*X?2E@&G
MW9]EXK2G#BE2@[-1C^;/YR?^"@G[(OB3]BG]HJ]\!"*Y.@W<C7_A34V./.MM
MQ'WO^>L>5!P<@D-WQ7ZN_P#!''_@H(W[4_P+C^'?C>]CD\;^$+9(-2)?#7MO
MNVQW2J>3P55CS\V#GY@*[[_@J?\`L0Z3^V;^SG>:+H]G"/%6@1S:AX5N)(P2
M;E5!\@GJ$EVA#[[3VK\0/V9?VB/B3^Q%^T99?$W1(+JWOM%O7L];TE_D:>`-
MB:W;CDDJ`!TW(#U`KAGSY/B[Q^"70^DH>R\1.%72;_VJ@M/-?\,?TM2MFW+>
MU?S8_P#!0H#_`(;A^+H'3_A/M7Q_W^>OZ&_@I\9O"'QZ^&>E?$_P)J\=YI>K
M6B3VLJ,#\K#H<=&!R"/:OYY/^"A*[?VX_B\GIX^U@#_O\]=6>ZX>G+S7YGE^
M$U*I0SO%TZFDHTV?IQ^S&^/V;/AZ,?\`,CZ3_P"D<5%-_9D_Y-M^'O\`V(^D
M_P#I'%17<HJQY%5+VLO5GX_>"_\`D<=(_P"PK;_^C5K^HGP)_P`BII_'_+G%
M_P"@"OY=_!`#>,](4G'_`!-+?_T8M?U$>`]P\*V".,,+*+(_X`*\SAQKV<T?
M2>,;7M\(KZJ+-BOA_P#X++_L#7/[5/P0E^(W@/2U;QGX0M6FTX``&]MLAI;8
MXYY&YE_VA[U]P54O;6+[*[7$F4"?/NZ8KW\10AB:+ISV9^1Y9F>*RC'T\5AW
M:47^'4_G-_X)Y?M@^(OV)/VC]-^(-PUU_8EW*EAXPTT-S-;,Q5F"GK+$VYN>
M?W;`<G%?1/\`P<#>*_#/CCXQ_#GQIX2U6*]T[4O!1NK.Y@Y22)I&*M^(_6LS
M_@MG^P._[.'QA'Q\^'^F`^%/&MU+)=)''B+3M3#>8X(_A23<SKZE67C.:^._
M'/Q7\4^//!GA3P/K\I>#P=:7%II+L^YEMY9_/6(^H1BX'L0.W/Q>)K5L)2J8
M.2]/,_I+*</@^(,VPG$."TDERU%W6S;^9^M__!M]S^RMXR'_`%4.;_TALZ_1
M<G#X'<5^=/\`P;?+G]E3QF<]/B'/_P"D%G7Z+JIDRP.*^HRI..#C<_!^.+3X
MJQ37\Y^7W_!QG^SS?:YX6\)_M)Z!9/(=$D;2=;*1[MEO,1)%(>^!)'L^LJ5\
M<?\`!(3]KS3?V3OVM;"X\87GV7P[XJC.F:S(6.V-W.Z"7GIME)5C_=D)[5^[
MOQA^"_@[XW^`M9^''CZR2[TK6[![2\MW0?<88W`]F4_,#V(![5_.[^V[^Q7\
M1_V)?C%=_#KQE8RW&ESS/-X=UEHCY&HVW(['@CD.F<\\''(\O-J53"8J.,I*
M]MS]'\/,?A.(,CJ<.8N:BW?E;ZW_`,M#^D/0K^SU*V%W83+)"Z*T;IC#*<D$
M8]1S^-7J_''_`();?\%KX_@KX=L?V?\`]J-Y[K0K6-(-"\5KOEDLHE)`CN1\
MS,B@J!(/NA<$=#7ZN_#KXZ_#'XL>&[?Q9\.O&VDZS87*[H[K3KY94(R1U7Z=
M#R*]G"8ZCBZ2DI*Y^89_PSF?#V-G0K0;BG92MHUT9V-07LD*C9*"=RG:`.OM
M56]\1V>FVWVS4)8HH@I:1WD`"@=R:^._V[_^"RG[._[,FB7/ASX?:U8^,/&C
M1R1VVDV%T&@M9,?*UQ,,H@!'*@ECC&!G-;U<11HQYIR2L>;@,KQ^:5U1PU-R
MD^R.`_X+S_M@:+\)O@$/V?/"FKHOBCQF5AO(T8%K32URTC^Q=PB#ZD_PU^97
M_!/+]GK4OVFOVP/!?PRM[-Y+,:HE_K+A,K':6^)I-W8!L*GUD'K7"?%KXL_%
MC]ISXM7GQ$\?7MWK?B;Q%>(#%%$S._\`#$D4?)`12451R!@X;J?V@_X(Z_\`
M!.S4OV/_`(;S>/OBC91)XW\2QYO+<*"-,ML*4M5()&X-N9R..5'\()^7C[7.
M,SYK>Y$_<\4\'X<\&RPBDI8FK&[?6[W7R/M70K(V$36Z*!$BJL:J>@`Q^%7R
M,C%16\?EDC=V'%2U]=9+1'\^)R:O+=Z_>4M2M(=1L)+&XA62.9-LD<B@@@]0
M0>V*_%C_`(+/?\$6[[X57&I?M:?LJ^'"^@SO+=^+_#%JNY],8G<]W;+SF(Y8
MM&,[>"HP3C]L3$>S8_"JNIZ9;ZE$;2]1)(G0JZ.F0P/4$'MCC\:Z,+BJF$G=
M;'BYSDF$SG#\E5>\MF?R(2)%<J&0`#`/#<8_PK[`_P""'_QNT;X'?MZV'B77
MKQ8["]\&ZW'<R,,!1#9RWI'/3(M%_/'6O:O^"YO_``25L?V>?$%S^UA^SKHF
MSP?J=V#XJT6TC"C1+B0?\?$>,%8)&!##D(\@Z*>/SC\(:A>:=K=G=6EQ)`Q9
MX6DC?:2DB%&!/8%6(/L37T&(Q'M<MG..ME=GY+DN2U,MXSPN$KNT95(QOY-G
MTE96_C3]N_\`;.5Y3++JGQ'\<;CA>(89YMQ8CLD<9P?]F,BOZ-/A1X)T/X:_
M#G1O`&@6?V:QT;38K2TA'\,<:[%_,`'\:_(C_@WA_9I;QU\;?$O[1FK6F;/P
MA9QV6EN\>0UY<AG?'^Y&.1V\X<\5^R=O:J8E\N8D;<`XZBOSS(Z-J,JLOM-_
MF?V#XFYFJF94\MI.\*$$OG9?H3SH9K9HU&2PQ_\`7K\R?^#BW]G#4O$OPW\(
M_M(:!IK22>&9)=.UUD3</LLS*T3MZ!)L\]O-R>`:_3I5V@#/2N6^,GPN\+?&
M+X<ZO\-?&NFK>:7K.G36E[`ZY#1NN#^/<'L17I8RA'$X>5-]3XOAW-)Y)F]'
M&+[+U^>C_,_!#_@E!^UQ:_L@?M:Z=KOBO5?L_AKQ+!_8WB#<^$CC=PT<[9Z;
M)$3GLK2Y^\*_H,M-3L]0B2YLYDEC<`JZ'((_K7\X/[='[%WQ'_8<^,EU\/\`
MQ7833:%<R[_#>MF/]UJ$)`PI8YQ(HX9.ORDC.:^L/^"7/_!9]?@;IEA\"?VH
MY)[KP[:*(=+\4;C)/I\0&U8YDY:2,'`5UR5!Y!QFOG\MQLL)-X>KI;8_6^.^
M'(<2TEG>5>_=+F2W?_#'[,QGDBG5QOPV^.OPN^+N@P>*?AEXRT_6M/N(U9+J
MQNA(N",C.W.T^S8/'2NBN?$-G:PFXDFBVCJ1)G'UQTKZ=3@U=-?>?B%2C6I3
MY)P:?:S+4LJPC)%?`W_!=G]M;1/@_P#L\CX`>$];4^)/'D3V]PEL06M=.!7S
MG?\`NK)D1XZL"^,[3CK_`-NS_@L5^SK^R[X>O?#'A+6;+Q?XR:(I#HFCWH>.
M!B<!IYAE(QU.,[N.G-?B=\7?BS\5?VH/B]>?$3QM>W6LZ]K]\%@A@0M]XD1P
MPH.0H)VA1G)Y[UXF:9BJ,73IN[9^G\`\%8C'8N&8X^/)0AKKI>WJ=1^PC^SK
M>_M0?M5>%?A186,DUK/J"76L*R[MEA`ZO-G_`&2G[LGU<#N*_I2AM62%(F`^
M50/7I7PU_P`$:?\`@G7=?LI?"QOBO\2;/R?'7BF!?MUNZ9;3K,-N2U![%B%=
MQW;`(^0&ONL#!SFNC*<-[##\SWEN>7XB<1QS_.N6D[TZ7NQ_4_.S_@X0_9<U
M'XF?L^Z-\??#&E-+>^`);C^TC'G<=.G5!(YQU\MXXW!/0;O4U^;7_!-G]L:X
M_8Q_:AT[XC3S7']AZI&=-\36R*6S9O(A+JO]Y&4.,<X5@/OU_1!XW\':5XZ\
M.77A/7K:*XL+^UEM[VWFB#I-$ZE71@>"""017X%?\%.O^"</C7]B#XHW&JZ)
M87%]\/\`5+G.@:P1G[,S#=]DF;)VLOS89L!E7/7(''FN'JT:RQ-%7?4^EX`S
MG!9EE57A_'OW9?#?[S]]_"_C#PYXTT>U\0>&-7@OK.\@2:UN;:0.DD;#*L".
M"".<UJ1D;BO<=:_!7_@F]_P5P^(?[%\\'P\^(&FR>)?`A<F.S\XBYTHD'FW+
M':8^F8SCN0PY!_7W]GO_`(*&?LG?M+Z+!J_PO^+^DS7$RJ9M+O+@6UW"Q'W&
MBEVL3U&5!4XX)KT,%F%'%T[WU/B>(N#<VX?Q#4H.5-[26J_#8]PK)\5#=X>O
MO^O-_P"568->L+N`3VLRNI&>#C^E<[\1O'?AKPUX4O;W6]8M+6+[*P\VXNXT
M7D8SDL*[95*:IR=^A\Q0I598F$5%WNNA_,IJ"E?B)/[ZZ?\`T<*_IZ^&O_(@
MZ*/^H3!_Z`*_F%NW2?X@S.C9']L@E@01DR+D#Z'C/>OZ>/AHV?`.B$=]*@_]
M`%>!D/O5:K7<_7_%Z,HX?+[_`,G^1LOT;_>'\Z_$+_@X0_Y/4TS_`+$ZV_\`
M1LM?M[)PC-[K_.OQ"_X.$/\`D]33/^Q-MO\`T;+77G&F#1\WX7R4>+(-_P`K
M_(^R/^#>'_DQ_4".WCV^_P#2>WK[^K\\/^#?7Q9H&B?L4ZA9:KK%I;2MXYO7
M1+FX5"R^1;\C/;@_B#7WD/B5X([^*M-_\&$7_P`575@:E-82*;1X'%=*L^),
M4^5_$^C[F[16"WQ*\$=$\4:<3Z?VA%_\52)\1_"UQ<BTL]?TZ61L;8TOXRS'
M(X`!))YX%=:J4V[)K[SY_P!E5_E?W,WZ^/O^"Y_/_!.WQ=_U\67_`*4QU]@]
M:^0/^"YR_P#&NKQ?)_=N++C_`+>8ZRQ37U:?HSV.&G;B#"O^_'\S\PO^"'YS
M_P`%(_!G_7CJG_I%+7[]CD#-?@'_`,$/,O\`\%(O!N!TLM4'_DC,?Z5^_HZ5
MY>0*V!MYL^R\5VGQ/I_(OU*VH1228"*"`K9XZ>GZU^//_!>C]@J7P-XK'[8O
MPQT9ETO6)H[;Q;:P)\L-T5_=W(4<*'V[6/3<<GK7[&2QM)]U\<$5S7Q0^$GA
M'XP>`M4^&_CS3H[[2=8LWMM0MIDR)$92I^A`.0>Q`-=^/P<,;A94WN?(\,Y_
MB>'<WABZ>L5I*/='X_\`_!"W]O>U^#GQ%;]EKXE:OC0?$MRS^'KB5LQV=^5)
M:+)Y42X``/&Y5[L:^4/^"@LB3?MO?%N5&&'\>:N0N><>?)@X]#1^V+^S/X]_
M8G_:1U'X7ZM-<1OIUV+WP[JN=IN;3S0T,Z'^\&7!]&5A_#7GWQ3\?:G\4_'^
MM?$?6X$CO=;O)[R\6,Y!E<$L>>>3S^-?&5<555*&#J+6#1_2&3Y/A:F:U,[P
M37LZ]-W2[GZ\?LR?\FV_#W_L1])_](XJ*/V9"/\`AFWX>\_\R/I/_I'%17UT
M?A1^,U4_:R]6?G/X-_X)V_MNVOC'2KF[_9A\9QQ1:E`\KR:0RJJB126)]`.:
M_H?\"V]S:>'+2UO3^^BM8DE&,;6"@$?45KB-!SM%.'TJL#EU'`7Y-V>#Q1Q=
MF'%4Z<\5&*<>R"D=$=#&Z@J1@@TM%>@?*'FW[4W[/?@;]I;X,ZW\(/'6G^=9
M:OITT(<<O;RE?DE3/1E;!'OQT)%?S[_&#]@O]JOX1_$S6_AQ=?`SQ9JITB^:
M!-4TCP[=3VUVG598Y$C*L&4@\'@DCJ*_I1J.2VBD.6B0_45YV.RVEC6FW9H^
MTX2XVS'A1U(TES0GO%NWZ,_/_P#X-\/A[\0OAQ^S+XLTCXA>"-9T.ZG\>S2I
M:ZSIDMK(\9L;4!PLB@[21C\*_0&'[O2A((H^(T`'H!3ZZ\/15"DH)['SN<9C
M+-LRJ8MQY>=WMO8*\S_:4_9>^#?[4?P[N/AS\7_"<&I6DP!@D(*S6\@P5DCD
M7YD88ZCJ,@Y!(KTRBM)14U:6J.&C7K8:JJM*3C);-'XB_M5?\$"?V@_A;J=U
MK_[.=['XVT4R/+%9F407]NN?]7M8A)C@D;@RGCE>17RCJ?PS_:Y_9UU42S^!
M?B!X.NH),I<+97MJQVC&%E10#TZY/U-?TSE0W!%1M:PL<F%3_P`!%>-6R+#5
M'>FW'T/TO`>*.;T:"HXVE&O%=U9_?9G\S>H?$[]L3XM.?#VO>.?B1XD:7$;6
MT^IWMT7]%VL6+<]N:]-^`G_!)/\`;G^/E_`(OA!J'AFPEE'F:IXOMVM(XP3]
M\1MB60]P`B_6OZ%Q:VHY^S(/?:*>B1K]Q0/H*RAD-.3_`'TW+\#JJ^*^,I4>
M3`86%%]UJ_R1\:?L`?\`!'OX'_L<S1>/?%$B>+/&;H2VL7EOMCM&)Y\B+)"'
MI\YR_7D9Q7V(EO#$5PN-OW0O0?\`UO:K-&!Z5[5"A2PT.6FK'YGF.8XW-L4\
M1BIN4GW&1$%V.#FGT45L<*OU"FR@8IU%#U&8'C?P%X/^(_AC4/!GC?P];:GI
M>JVCVVH6-W'NCGB9<,K#W'\AZ"OYFOVY?V/_`!)^QC^UAKGP.DTZ]GTVWNQ>
M>';R2$L;G3Y6_=/N'#$$,C8_BC<=J_J$K%U/P+X8UJZ2^U?P[8W<T8`66ZM(
MW90#D`%E)`!YZUO1Q$Z4)P>JDK'D9AE%''XJAB&[3I24D_1IV_`^?_\`@DU^
MS8/V:_V+_"_AG5;'R-8UBT36-:3;AH[BX42&-CU)0;4_X#7TP%7`VC&.E-@M
MX[<;8T"C:``HP`!^E25S0A&G%1BM$>_B\35QF)E7J.[D[A45P@DPA8C@]#4M
M%4CF:NK'F'[1G[,_PA_:?^'UQ\.?C%X4M]4L)GS&\HQ+;R8XDC<?-&XSU!%?
MDU^UC_P0.^/_`,-+NY\0_LZ:I!XVT/K;Z;,1;W]NN?NX/[N<#KD,I_V:_;2D
M*J1@@8KBQ&7X3$ZSCKW/I.'^*\[X;FOJE3W>SU1_,QJGPI_;!_9TU/S+KP%X
M_P#!TT1^:[BL[RT!9>X:,!6QG@ACU]Z74?BC^V-\5T7PYJOQ!^)'B,,/EL[C
M4;Z\WCV3<W'UK^F-K:V/WX%/U44GV6S_`.?9/^^17F/(FG[M5I?UYGW7_$5%
M/WJN`IREU??\#^>#X$?\$H/VY/CYJ$$>F_!O4/#-C+(%?4?%MLUC'$IZML;;
M(YQQQ&"217ZF?\$__P#@CE\$OV2;F/Q]XVF3QAXU3:T.LWUIMCL&P0?LT9)V
M'G`<_/@<;<MG[75$7[J`?04M=F'RC"4-6KONSYK/?$#/\\INDY*%/^6)!;VU
MO;1".`;5'``Z?E4_2BBO3C%15D?#W;>HV3&0:YOXD_"GX=?%SPK=^"OB/X3L
MM8TR^C*7=E?0B1)![@]QP01R"`1S7344G%2T94)SI34H.S74_(O]KO\`X-[_
M`!#9WESXR_9#\8136S?O/^$7UN8J\1SR(K@@[AC^%P#Q]ZOA;XD_L6_MA?!&
M_E?QY\`O&&GFW8@:A#H\TUNI_O":$.I'_`OP%?TNX'3%->*)_OQ!OJ*\G$9)
MA*KYH>Z^Z/TC*/%'/\OHJCB%&M#M)'\QFD_%K]J3PY:C3='^(_CZQC0;?)AU
M>]C"^N!N&.:U;#X._MD?&B8QVOPQ^)/B8L=I^T:9?W<:G_>9"J_F/J*_I;-I
M:DY-JG_?(I5MX0<^2@^@K".223LZK:_KS/0GXI1M>E@*<9=]_P!#\&O@%_P1
M'_;M^*6L6-]XO\*67@[3@Z.USKMVIE`W9P((BYS]6'45^Z/@O2I-#\*:?HT\
M@D>SM5@=U7`8H-N0,G@XK7"*.BTM>GA,%1P<7[/=GQ'$G$^9\45XU,6U[NR6
MR*TI/EG`].OU%?D/_P`%O?V2OVD?C=^UE8>*_A+\%_$/B'38?"T%N]]I5B98
MQ(LDA*G'0C(K]@::T:-U4?E58K"PQ=+DEL<_#N>8CAS,UC:"3DE97V/YP++]
M@']O[3H?*T_]G+Q[!&7W;(=.D52V",X!QG!Q4G_#`_\`P42_Z-Z^(G_@'/\`
MXU_1T(8\8VC\J=L3^Z/RKSO[$I6MS,^YGXK9K4FYRP]-M^1_.&/V"/\`@HCG
M`_9Z^(F3_P!.<_\`C7H'[*_[%/[>/AC]H_P+X@\4?`OQY!I]EXNL)M0FN[:5
M(X84F4L[DGE0"3@^M?OYM7^Z/RH"J.0HS]*=/):,)\W,SEQ?B7F&,P\Z4L/3
M7,K:)B1;O+7=UQS7R]_P6&^%WQ`^,7[#/B;P)\,_#%]K.K74UJ;?3M.BWS2[
M9T)(!],5]1TA4-PPS7K5*<:E-P>S/@<!C*F7XVGB8*[@T]?(_$__`()"?L7_
M`+5?PH_;L\+>/_B5\"?$/A_1[.WU`W.I:E8&*./?93(J%B2"2S?I7[8CD9I!
M'&#D(/RI:PP>#I8*ER0/2XBX@Q7$F/\`K5>*3LEIY!1THHKK/!/C?_@KW^P?
MI_[7?[/5SXG\'Z,)/''A6)KWP^PCR]TN1YEJ<`L0R[MH'\6/4U^*<G[)_P"U
M(C%&_9F\?'$;Y)\(WI.-I&,"'&2<<YQS7].;*K#:PX-,-K!G/DK^0KR<;E-'
M%U543LS[SAGC[,N',#+"QCSQ>UW:WX,_//\`9Q\#>.=,_9Y\!Z;JO@S4[6ZM
M_!FEQ7-M-8S*\,BVD09&!3@@@@CVHK]#?(C_`.>:T5V+#V6YXLN(:LI-\N_G
M_P``?11174?.A1110`4'/8T44`%%%%`!1110`4'/8T44`%&`.@HHH`****`"
MBBB@`HHHH`***3<OJ*`%HI-R_P!X?G2Y![T`%%(&4C(8$#KS070=6'YT`+10
M"",@T9'7(H`,9ZT8'H*,CUI-RGHP_.@!:*3<O]X?G1N7.,B@!:*3<IZ,/SH#
MH1D,/SH`4G!Q14<LP4A4(^8'!S]/\:YKPW\7OAQXT\4:UX(\(^.],U+6/#LB
M1:[IEE>(\]@[J&02H,LA*LK#(Y!!H%=7L=311D>M(64=6'YT#%HI`RGH11N4
M]"*`%Z=336=AP!S7#?%']H/X:?"KQYX/^%_BOQ&MKKOCNZN[?PO8^6S->RVT
M0FE4$`@;4(//K796SF2!2\VXG^+UJDNIE[:/.X+5HLT4A91U8?G1O3&=PQZY
MJ346BD#*>C#\Z-Z8SN'YT`+12!E/1A^=&Y<9W#'UH`6BDWH>CC\Z-Z9QN'YT
M`+12;E_O#\ZR?'7CCPK\.O!^I>._&?B*STK2-(M7NM3U.^N%C@M84&7DD=CA
M55<DD]!0)M(UZ*R/!7BK1O&WANR\8>'-=M=1TS5+.*[TN^LYA)%<VTB[XID8
M<,KHRL".""*UBZ#JP_.@=Q#(<<+0C,V<C%<[\2/B+X:^%?@/5OB1XVU5;'1]
M#L7O-4O&1F$$$8W.Y"@DX`)Z4[X6_$+PS\5/`>D?$OP9K27^B^(=*M=2T>]4
M8%Q;3PK+%(`><,CJ>?6G;0RC6C*5D=%11UZ44C4****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****``G`S7FW[5OQ9U?X$_LZ>-OC-H6E6
M]]>>&O#EUJ5M9W3E8IVAC+A&*@D`XQD#//%>DDX&:\7_`&^O#^K>,?V+?B;X
M;T31YKZ[OO!.HPVMG;1EY)I&@8*B@<DD\"KI_$<V,E4CAI<FY\P^$/\`@I[^
MUSID'PD^+/Q>_9I\.Z7\-?BWKVGZ/I-W8^())=5M9;P@6\\L6S9Y4A(88.0"
M-V#77?%?]OO]J'Q'\3?B1X:_9(^!_AC7]!^$05/%FI^)==GM)M1NQ`)Y;6QC
MAB<.Z+E29"HW+@9R,^?_`!I^$OQ,U7]@3]COP58_#_5I]2T#Q/\`#>3Q#906
M3F>PCMHK47#2#^'84;=GICWKS7Q7^SY\*O@1^V+\7YOVNOV<?B+XDT+QWXE?
M7?!?B/P1;ZA<P7,=RBF>QEBLG!617WC,@P0N00#7=%4'&[6I\Q4JYG":I\[M
MIJ?2_P`!O^"E;?&SX^^%?`UOX8M[#PIXZ^%!\9>'-7N7Q<&2.=X[JQ<#Y&,>
MS>6X)!SDCFN9_9I_X*RW?QL^%/QP^)_C+X;6NA#X6Z5-K7AZW^U28UG3"MY]
MFF(8*0TCV94@9'S+SS7FW[>/P.\5?"S]G7X)_'C]CK]G_7[6_P#"$%_IEEX-
M%FSWUGI^KZ?-`Z2H22IC+ACR=K`'M7(_M??L8?&7P!=_!WX(_![P%J.I:-\2
M?AIHOPZ^(>J65H673HK&^L9&OK@C&&9))\D]2CU2AAIZ)&=;&9I1::;?+OYW
MT_4_2+]E[XG>,/BO^SAX/^*_Q!\-6^BZQXBT"'4KW2;:1G2T,J^8L>6Y)"LH
M/;.<<8KXQUO_`(*I?M::G\"?%W[;/PQ_9J\-:A\'M"N+RWTR6[\1W$>LWPAE
M,"WX@2(QBV\TC<N\2!%=@IP,_>FG^%].LO!<'A2RC:"UM[!;6**,XV1JH50#
M[`"OR8UCXH?%+]FK_@E5\2/^">OC[]G;QB?&/A_0=7L?[:BT9O[%N-&:220Z
MC]K!V(/(\TA"=Y=57&6%<]",.=QM<]#,\3BZ$(N+LN1M^NECZQUK_@H%\?OB
M!KGP]^$/[,/PH\/ZEX\\7?#2T\:>(3XIU6>WTK0[6>.,JC/`DDDCO(S(H"X`
M`)/S'''>//\`@K)\3O#?[..E?%*R^`T5QXXM_C%%\/O&/@Q-2^2VO"MR2;6?
MCS-S11;=X"CS""/ES7AOB#X`:+X;\=?!G]ICXT?!;Q?XJ^&WB3X!Z#HU_?>#
MOM4EUH=_!;V\D3S0VDBRF-T.,@,!@]#7:?&3X"_#K6/V7?ASJ7[)_P"S1XQT
M'2K_`/:8\.:IJ5AK>FW*7URD,DBRW\D<[,\</)^9N2`#WKHY</\`RGGTL3FD
MZ#DY/9?BD>[_``B_;Q_:!\*_M(W_`.S-^VG\(/#?AW4#X%F\7Z+JOA+6IKZT
M^PPR%)HI6E1&\Y-K$X&"!P37$Z;_`,%3_P!H>/P'H_[7WB/]G[0;?X&:YXC3
M3K6ZCUV=_$$%G)<-`FH2V_E^3Y)9<E1(7`(XXKH?VH/@CXX^)_\`P4L\+R:=
MX=OQHM]\!/$&D7.MQV[-;6]S/-B-'<<*Q5V('<"OF+]E[]GK]F[P/\/-#_9E
M_:G_`&*?BE??$#2-8.FWB65GJ,VEZB/M6([])5E-NL)3:YR01M)P,XJ.3#\M
M^4*N(S2%54U)\J/JC3_V_?VF_B+^WEXR_9#^"_P"T*_TSP1?Z8^L^++_`%AH
MHH=/N+>":0A=OSW&Z8A(QD%5R3UIW[2W[87[=_[-.F^(_CSXJ_9T\$2?"OPO
MJ8BNXH?%<QUV:P,R1"]2(0^0,EP?*,@;@\=*O_L9_#7Q?X7_`&^_VF?$NI>#
MKZRTS5=5\.G1M0N[)TAO%BTN)',3GB0*?EX/!X[5^?GCOX+:YXT_9+\>>$_C
M)^R!\1?&'[2UW?7LVH^(M4TJXGMM/@%R6\^UN`P@6`0*^R*/<Q9P,<TH1IR>
MBL5B,3CZ.'2DVY-MJWE:Q]6?M%_'#]MK5O\`@I)\(=&^#&E^%IM!UCPEJ&H^
M'-'U3Q-=V]OJ-N4MVFN+Q(X2$EB#GRE4LK<[MN!GJ_"W[9WPR^!/BK]I_P"*
MWC#X+Z)H=Q\.-3L$U[4O#Z[;SQ'</9(T8E<]6W/Y:GC@@G'-87Q^U#QO\"?V
MI_V:/VC==^%?BC6?#.B?#V_T37;C0-)>]EL;NXBM1'YL48WKN.<G&/E/3!KA
M?BO^R-\9?VEO#/[9?A+P_P"!]5M+OQ;XIT?4_"'VZW-NFI&VL[>7RXV?`))C
M*'/`8@$YSB^6F]'L<].MF$-8MN5V]?-(]AT#]OS]L#X:^+/AW<_MA_L_^%O#
MOA#XI:I!I^C:EX:\0375WHEU/&9+>"_CEB107PJEHRVW=ZC%8&L?\%%/VZ_%
MOB_XRZ+\#_V9?"&I:9\&O$E[;ZKJ&N^)9H3J-I"C2Q)`JQMFX*([,"0JYC&<
ML0.8^,WQ8^(?_!1[5_@W\"?#'[-_CGPS=>'O&]AX@^(6I>)/#TEE:Z.;*-_,
MA623_6NSEU7`P0%]:](_9)^''C_0]6_;!D\0^!-4LEU_X@:C<:+Y]FRKJ,#:
M<$26`GAPQ&,CO4N-!0YFM3H]MF$L0J<)/EL^C['TS^R3\>=/_:@_9P\'_'S2
M--DLX?%&B1WOV.4@M;NV0\9(X.U@RY]N:^5[']OO]N?XJ_$3XL>`/V?_`-G/
MP??K\(/$<]GJ5_KVOSVJZC$D:R)'`J(S?:'7S#\V$&U<D;A7L7_!)+PGXM\"
M?\$[OA=X4\<^&[O2=6LO#S+?Z=?PF.:"3[1*=KJ>AP17R/\`L^_M<:Q^R_\`
MM%?M26^H?!#QGXGMM2^)4SZ)/X5T-[U9-26V5!:3;,F$LAMR&?"D`\]JQIQC
M-O0Z\;B<33I8=.5F[I_)7_0C_:F_:^UO]HCQM^QC^TO\%OAT^HZUJVN>)$L?
M#%Y>B%4U!K.*V>&63;\L:2,Q9QSM7(SFOIC]EC]L?X]_$?XL_$O]FO\`:$^#
M^C:5X\^'VE6FIP?\(OK$EQI^JV]S&S0;'E17C<L-IR,8)]#7S1\#?V4_C5\)
M=3_8KLO$/@'4GO+#Q5XLUOQ8D%NTB:+]NM%,,<[KD1\,%(_O`@?=KN/CI\./
MVF(?VM/VI_&WP-\*ZI:ZSJ7P=T*V\'ZK%$8X[J[C23='#*QP74%OH371RTI1
M47H>;AZF84Y2KR;=[-KOHCNH?VV?VTOA!\5O`NA?M<_`WP3I7AGXB^(H]#TZ
M3PCXGN+V^TJ]E1C"EPLT4<<BEL`M&Q"@D\D8J+X;?M[_`+4'QI_:H^(7P/\`
MAO\`L_:'+X;^&/BUK+Q1XIO]99-MF8FV>7%M!>Y9HY<JO[M5VG.6%?'V@_!S
MX<Z[XE^`.N?`/]C;XAVGBG0_B'HDWQ+\<^)M!NUE649,T,DLQ)FS(9&+H"BX
M&6[5]H_L$_#_`,9^'/BK^U1?Z_X5O[*+6_BO-=Z//=V;QB\A^QJN^+<!YB[@
M>1D<\43A14;HJAB\TK34+M+5_@>-M_P5[_:\T;]FNT_;;\3?LR>&D^&EIK\N
MD:Z++Q+(VHRRB_:T$UM$Z!#&"%7#DL9-W`0`U[?\$OVU/VI8?VLM'_9C_:S^
M"'AOPZWC+PU=:YX2O/#NO27GDI;X\VVN]Z*!*H.=R%E.>O6OF3Q#\$OC5)_P
M0M@^&D'PKU]_$8^)4ER=#DT]UNC&/%$DN_RR,[/+^<>JX/>OI#]H_P``?%+4
M?^"H7PG\;^"_"UW+:V'PO\3PMJWD'[);7DB)Y"2/T5F(/<<"L^6FUL5"690J
M<RE)VL_\RM\>OVT_VX?V9K6_^.7Q2_9U\#I\+=-\0I8W4-AXNN)-<%C)=BWB
MO!#Y(@((9&\OS-PY&*VOC1^W9\;?$/[0,?[)?[%?PAT;Q+XKL_#D&O\`B?5?
M%>JR66EZ59SL!#&[1(\C3N"K!`I`4Y-?GI\0/@O_`,)I^R?K?A_Q?^Q]\3O$
M?[1;:_\`:/$OBW6-'NIA8!=15EFMYW9HI(O*\M5CC#'[Y[5]9)>>/?\`@G_^
MW1XJ_:5\7?!7Q9XE\`?%;P1H5K<ZKX4TA[^?1=4TZUCMQ!+;1YD"R(I.X#`;
M@T_94K:J[*CF&-E5:;:AUT9Z?\1?VR_VI=)\>>#/V4?`7P<\&W'QFU?PK+KW
MBR'4?$-PFB:'9).\*2>=%$TTOF/'M0>6#ZXKF)/^"IWCA?@=%XKU;X1V%GXS
MT'XT6?P[\<Z%/J+O;6MS)<I%+-;RJNZ1=C;TW`9#<UY/^UKX-T3XC?M=^"OV
MY/BI^S?\1=0^&GB/X<?V+J=CIVGW<>JZ#>PWD\MO+<6MLZS;)4E(P`<9.<8Y
ML_'3X#^"6_83E^)'[&/[*WC73(=-^+>D>)]7\/:S9W":KK26<J;[E(;AFD9F
M7;C=AB%SCBFHPY5H$\5F-6O/EDTHZ)6W1]0_'#]JCXJ^`/VP/"?[*W@#P3HF
MI77BWP'J^MV-]JM])"L=Y:AO)B<(C8B=L*[CYE!!56YKY+_9,^-G[5&I_LZ_
MM0>*_P!H/P)X0\6^#=$\6^*CK=AJVOW-TWVZ*SM"=*CB:%5.GB/;A\A\R-\O
M6N]\%?%KQS^UA_P59^&'QU\-_L^^-]!\$Z+\/M9TZ+7O$^@R62W%PZ[W4H_S
M1@$JJEAASG'3GCOAA<>-O!?P0_;`_9(UWX,^,$\3>)O%'B_Q-H<Z>'9GL;RR
MGL;.*$17`'ER2NR,1$#NQ@TDE&/F35K8K%8KVG,U'7H]=$>O']O#QCX2^$WP
M`^#G[,OP#T?4_B%\4OASINKZ)X8>^-GH_AS3?L,#DRS*&811[]B!$8L(\<<9
M],U3X@_\%#=/^"MI))\#_AZ_Q*N/$OV2\@/BV=-&MM-$#-]O,WE><V'V1^4$
M#$L3C'-?+]MX"^,O[*VM_LN_MEO\(_$'B31?#_[/VE^$?'VCZ#IYEU#1]MI`
MPN/L_P!]U#/*KHHW`QCVJ[^W!\:=4_:GC^%7Q*UGX)?%1?@A;^*;Z'QWHUKH
M=S::A/(ENAM+F:WC(G:V+NPP.I!SVPO9Q;1M#&XF$)NIS<VR7D=?\1_VN/B?
M\6_V<?VD_P!F[]H;P+I'AWQ_X`\!7$VHGPWJ4MWIUY:W-DSQ3P22HDF,-R'4
M$$CBL_X6_MB_&SP%\$?V8_V1?V:OA_X8U3QEXB^`6B:W)?>-=:FLM.M+2+3;
M=`H:WBDD>1FC?Y0O``)X.:\:^$/P,U73=4_:OO?@K^REXA\"^%_%/PFAC\%Z
M'?:4T)NI1;R(2J'+*\A4-Y3-N7<<@<"N]^+F@_`1OV-_@5\,/VF_V7?B?>^)
M=$^#>A'PUXL\#^'KEK_2-22RAC-JL]N=]K.LL:MA_DYYS@UHHTO::ZHY(5<?
M*G*I=IVM_P"37_(^P_#_`,0?VMY-!L7\3?#7P=#J36<1U"&V\3RF..?8/,5"
M8P2H;(!(!Q17YL^#O"7_``<+IX1TI=$U"Y2R&FP"T36FMS>+%Y:[!.>\N,;S
M_>S14<L/([EBZ]OAD?L[1117`?6!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!UJ(V\3Q>6PRO3%%%-;">KL)]AM!\OD@9.>">M*UI:]XA
M[9S111=DN,>Q$NGV:*$6+`'0`GU)_J:!I]L/F6(##$_B22?U)HHIINXDHW>@
MZ*&*)2B,>1T-?&OQ._X)N_M5?&G1;_X6?%W_`(*+:MJOP[U6_+ZGX?M_`EO;
M:C=6ADWBS;4$N,[,[02(02N5/#&BBE&<J<W8PKT:>)BO:'UEX'\#>'_!/A33
MO!F@V*0:?I%A#96$"<"*&-%15&.@"JH_"MDVENRX>,'%%%)U)-W-H4:=-<D5
MH(MG&K;RO3/\1[T?8+,\B(`8P0!@8HHI<\F:.$)*[0"UMUX2+`[`'ITZ>G2D
M.FVC@CR5.3GG/!XZ>G04455W8AJ-]@%A;])DSSD4W^R[=/\`CVB"#'&TD>_\
M^?K112&FD[V'FR4X)B3(Z''.?6E%HI.77H<\$CVHHHV&K-;$@ACC38!@5XC^
MR_\`LC']GCQU\4?&-QX]763\2O&S^('M5TK[.-/S`D7V<-YK>;C8#OPG^Z**
M*N#:V,YT*56I'F6U[?<>S6]I:I\B*=JD8&3@8_\`U4XZ?:[1OBW8/R[F)Q^=
M%%2[MIC48I-6&#2K/<&\A<C(!QV[CW'M3O[/@C&$C"\8&***$W<;C%IZ"?9(
M3(%=<@CD9IXLHP,.I(R>K$]\T44YR:*BEM;H-DTNRE7;Y([G()&,C%$-A"A)
M,8;.?O#/?..>WM114J3>HG&$79)"C3;$'>;=0?8>Y/\`4TOV"W4Y6-0I;)&.
M"?7ZT44<S;L%HQ=TMR.32-/D7`@52>ZY!QV&1Z9X].U.&F6`D,OE`L0.I/&,
MX(]#SU'/3T%%%.[1,8Q:6FPOV"W(PB`=.A-,;1[)^MJ@YZJ,>OI]2?KS1123
M=BI*-]@@TC3H)"\=L/F.<$Y`X`X!X`X'`^O4U))I]F>L"],9'!_.BBEJM;A&
9$+6L1MI6G,Q9K-"2<DD4445%V5RQ['__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
